Frankfurt - Delayed Quote EUR

LAVA Therapeutics N.V. (4PKB.F)

Compare
1.2200
+0.3400
+(38.64%)
At close: 9:55:01 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
7,345
6,769
19,391
5,350
3,747
Cost of Revenue
154
3,482
--
--
--
Gross Profit
7,191
3,287
19,391
5,350
--
Operating Expense
35,230
46,540
54,229
48,963
18,420
Operating Income
-28,039
-43,253
-34,838
-43,613
-14,673
Net Non Operating Interest Income Expense
3,272
2,970
257
-625
-342
Other Income Expense
-2,564
-1,412
2,923
2,040
-869
Pretax Income
-27,331
-41,695
-31,658
-42,198
-15,884
Tax Provision
311
279
249
157
43
Net Income Common Stockholders
-27,642
-41,974
-31,907
-42,355
-15,927
Diluted NI Available to Com Stockholders
-27,642
-41,974
-31,907
-42,355
-15,927
Basic EPS
-1.01
-1.57
-1.23
-2.30
-0.63
Diluted EPS
-1.01
-1.57
-1.23
-2.30
-0.63
Basic Average Shares
27,126.3260
26,732.5560
25,924.0050
19,758.1690
25,352.2570
Diluted Average Shares
27,126.3260
26,732.5560
25,924.0050
19,758.1690
25,352.2570
Total Operating Income as Reported
-28,039
-43,253
-34,838
-43,613
-14,673
Total Expenses
35,384
50,022
54,229
48,963
18,420
Net Income from Continuing & Discontinued Operation
-27,642
-41,974
-31,907
-42,355
-15,927
Normalized Income
-25,739.5120
-40,571.8840
-34,806.6160
-44,386.8400
-15,275.2500
Interest Income
3,504
3,202
339
--
--
Interest Expense
--
232
82
625
342
Net Interest Income
3,272
2,970
257
-625
-342
EBIT
-26,249
-41,463
-31,576
-41,573
-15,542
EBITDA
-25,210
-40,185
-30,795
-41,015
-15,078
Reconciled Cost of Revenue
154
3,482
--
--
--
Reconciled Depreciation
1,039
1,278
781
558
464
Net Income from Continuing Operation Net Minority Interest
-27,642
-41,974
-31,907
-42,355
-15,927
Total Unusual Items Excluding Goodwill
-2,564
-1,412
2,923
2,040
-869
Total Unusual Items
-2,564
-1,412
2,923
2,040
-869
Normalized EBITDA
-22,646
-38,773
-33,718
-43,055
-14,209
Tax Rate for Calcs
0.0003
0
0
0
0.0003
Tax Effect of Unusual Items
-661.5120
-9.8840
23.3840
8.1600
-217.2500
12/31/2020 - 4/6/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NRXBF NUREXONE BIOLOGIC INC
0.3960
-5.71%
 
OSE.PA OSE Immunotherapeutics SA
6.64
+0.15%
 
AKTX Akari Therapeutics, Plc
0.9201
+1.11%
 
SLGL Sol-Gel Technologies Ltd.
0.5550
+0.91%
 
SYRE Spyre Therapeutics, Inc.
19.00
-7.99%
 
UPB Upstream Bio, Inc.
7.66
-0.91%
 
BOLT Bolt Biotherapeutics, Inc.
0.4600
-3.10%
 
XNCR Xencor, Inc.
14.38
-0.48%
 
PRLD Prelude Therapeutics Incorporated
0.8084
+0.30%
 
APRE Aprea Therapeutics, Inc.
2.5500
-0.39%